Abstract
Background: Foslevodopa/foscarbidopa (LDp/CDp) significantly reduced motor fluctuations in people with Parkinson's disease (PwP) in clinical trials, but its real‐world tolerability and optimal dosing remain unclear. Objectives: To assess tolerability, dosing patterns, and modifications to concomitant medication with LDp/CDp in clinical practice. Methods: A single‐center retrospective cross‐sectional analysis. Results: The LDp/CDp was initiated in 53 PwP (41% women, mean age 66 ± 11.3 years, mean disease duration 14.1 ± 5.7 years, median H&Y 4 (3–5); history of cognitive impairment: 40%, history of psychosis: 62%, previous device aided therapies failure: 39%). After an optimization period (18.4 ± 6.8 days), the mean Base hourly infusion rate was significantly higher than recommended (0.39 ± 0.18 vs. 0.32 ± 0.13 ml/h, p < 0.001) and the LDp/CDp was co‐administered with MAO‐B‐inhibitors (50%), COMT‐inhibitors (44%), and dopamine agonists (12%). Adverse events occurred in 40%: skin reactions (31%), psychosis (8%), falls (2%), and nausea (2%). Thirteen patients discontinued therapy. Conclusions: LDp/CDp may be an effective and well‐tolerated non‐surgical option for managing motor fluctuations in PD, though higher dosing and combination therapy are often required.

This publication has 26 references indexed in Scilit: